New Harbor Financial Group Exits Position in Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX) : New Harbor Financial Group has sold out all of its stake in Quest Diagnostics Inc during the most recent quarter, according to the disclosure filed by the company on Jul 19, 2016 with the SEC. The investment management company has sold out 200 shares of Quest Diagnostics Inc which is valued at $16,712.

Other Hedge Funds, Including , First Quadrant L Pca reduced its stake in DGX by selling 94 shares or 1.11% in the most recent quarter. The Hedge Fund company now holds 8,400 shares of DGX which is valued at $701,904. Quest Diagnostics Inc makes up approx 0.01% of First Quadrant L Pca’s portfolio.Ferguson Wellman Capital Management Inc boosted its stake in DGX in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 6,900 shares of Quest Diagnostics Inc which is valued at $572,976. Quest Diagnostics Inc makes up approx 0.02% of Ferguson Wellman Capital Management Inc’s portfolio.

Quest Diagnostics Inc opened for trading at $83.5 and hit $83.86 on the upside on Wednesday, eventually ending the session at $83.56, with a gain of 0.49% or 0.41 points. The heightened volatility saw the trading volume jump to 9,64,586 shares. Company has a market cap of $11,820 M.

On the company’s financial health, Quest Diagnostics Inc reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $1.32. The company had revenue of $1906.00 million for the quarter, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.25 EPS.

Many Wall Street Analysts have commented on Quest Diagnostics Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 76 from a previous price target of $70 .Company shares were Reiterated by Barclays on Apr 22, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $72 .Company shares were Reiterated by Mizuho on Apr 21, 2016 to “Buy”, Firm has raised the Price Target to $ 84 from a previous price target of $75 .

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.

Leave a Reply

Quest Diagnostics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quest Diagnostics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.